Use and clinical interpretation of pneumococcal antibody measurements in the evaluation of humoral immune function

Clinical and Vaccine Immunology

Volumn 22, Issue 2, 2015, Pages 148-152

  Daly, Thomas M ^a   Hill, Harry R ^b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ARUP LABORATORIES   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE;

ANTIBODY DETECTION; DRUG CONJUGATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOPRECIPITATION; MENINGITIS; MULTIPLEX POLYMERASE CHAIN REACTION; OTITIS; PNEUMOCOCCAL INFECTION; RADIOIMMUNOASSAY; REVIEW; SEPSIS; SEROTYPE; SINUSITIS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VACCINATION; BLOOD; HUMAN; IMMUNE SYSTEM; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGY; LABORATORY TEST; PHYSIOLOGY; PROCEDURES; STANDARDS;

ANTIBODIES, BACTERIAL; CLINICAL LABORATORY TECHNIQUES; HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC DEFICIENCY SYNDROMES; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE;

EID: 84921991469     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00735-14     Document Type: Review

References (30)

1. Mirsaeidi M, Ebrahimi G, Allen MB, Aliberti S. 2014. Pneumococcal vaccine and patients with pulmonary diseases. Am J Med 127:886.e1- 886.e8. Http://dx.doi.org/10.1016/j.amjmed.2014.05.010.
2. De Schutter I, Vergison A, Tuerlinckx D, Raes M, Smet J, Smeesters PR, Verhaegen J, Mascart F, Surmont F, Malfroot A. 2014. Pneumococcal aetiology and serotype distribution in paediatric community-acquired pneumonia. PLoS One 9:e89013. Http://dx.doi.org/10.1371/journal.pone.0089013.
3. Sleeman K, Knox K, George R, Miller E, Waight P, Griffiths D, Efstratiou A, Broughton K, Mayon-White RT, Moxon ER, Crook DW. 2001. Invasive pneumococcal disease in England and Wales: vaccination implications. J Infect Dis 183:239-246. Http://dx.doi.org/10.1086/317924.
4. Schiffman G, Douglas RM, Bonner MJ, Robbins M, Austrian R. 1980. A radioimmunoassay for immunologic phenomena in pneumococcal disease and for the antibody response to pneumococcal vaccines. I. Method for the radioimmunoassay of anticapsular antibodies and comparison with other techniques. J Immunol Methods 33:133-144.
5. Lahood N, Emerson SS, Kumar P, Sorensen RU. 1993. Antibody levels and response to pneumococcal vaccine in steroid-dependent asthma. Ann Allergy 70:289-294.
6. Sorensen RU, Hidalgo H, Moore C, Leiva LE. 1996. Post-immunization pneumococcal antibody titers and IgG subclasses. Pediatr Pulmonol 22: 167-173. Http://dx.doi.org/10.1002/(SICI)1099-0496(199609)22: 3-167::AID-PPUL5-3.0.CO;2-M.
7. Landesman SH, Schiffman G. 1981. Assessment of the antibody response to pneumococcal vaccine in high-risk populations. Rev Infect Dis 3(Suppl):S184 -S197. Http://dx.doi.org/10.1093/clinids/3.Supplement-1.S184.
8. Quataert SA, Kirch CS, Wiedl LJ, Phipps DC, Strohmeyer S, Cimino CO, Skuse J, Madore DV. 1995. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin Diagn Lab Immunol 2:590-597.
9. Goldblatt D, Plikaytis BD, Akkoyunlu M, Antonello J, Ashton L, Blake M, Burton R, Care R, Durant N, Feavers I, Fernsten P, Fievet F, Giardina P, Jansen K, Katz L, Kierstead L, Lee L, Lin J, Maisonneuve J, Nahm MH, Raab J, Romero-Steiner S, Rose C, Schmidt D, Stapleton J, Carlone GM. 2011. Establishment of a new human pneumococcal standard reference serum, 007sp. Clin Vaccine Immunol 18:1728-1736. Http: //dx.doi.org/10.1128/CVI.05252-11.
10. Paris K, Sorensen RU. 2007. Assessment and clinical interpretation of polysaccharide antibody responses. Ann Allergy Asthma Immunol 99: 462-464. Http://dx.doi.org/10.1016/S1081-1206(10)60572-8.
11. Pickering JW, Martins TB, Greer RW, Schroder MC, Astill ME, Litwin CM, Hildreth SW, Hill HR. 2002. A multiplexed fluorescent microsphere immunoassay for antibodies to pneumococcal capsular polysaccharides. Am J Clin Pathol 117:589-596. Http://dx.doi.org/10.1309/LMCH-C4Q2 -VFL9-3T1A.
12. Lin J, Kaltoft MS, Brandao AP, Echaniz-Aviles G, Brandileone MC, Hollingshead SK, Benjamin WH, Nahm MH. 2006. Validation of a multiplex pneumococcal serotyping assay with clinical samples. J Clin Microbiol 44:383-388. Http://dx.doi.org/10.1128/JCM.44.2.383-388.2006.
13. Marchese RD, Puchalski D, Miller P, Antonello J, Hammond O, Green T, Rubinstein LJ, Caulfield MJ, Sikkema D. 2009. Optimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulinGserotype-specific antipneumococcal antibodies in human serum. Clin Vaccine Immunol 16:387-396. Http://dx.doi.org/10.1128/CVI.00415-08.
14. Pickering JW, Hoopes JD, Groll MC, Romero HK, Wall D, Sant H, Astill ME, Hill HR. 2007. A 22-plex chemiluminescent microarray for pneumococcal antibodies. Am J Clin Pathol 128:23-31. Http://dx.doi.org /10.1309/781K5W6QH7JH2TMA.
15. Balloch A, Licciardi PV, Tang ML. 2013. Serotype-specific antipneumococcal IgG and immune competence: critical differences in interpretation criteria when different methods are used. J Clin Immunol 33: 335-341. Http://dx.doi.org/10.1007/s10875-012-9806-9.
16. Whaley MJ, Rose C, Martinez J, Laher G, Sammons DL, Smith JP, Snawder JE, Borrow R, Biagini RE, Plikaytis B, Carlone GM, Romero-Steiner S. 2010. Interlaboratory comparison of three multiplexed beadbased immunoassays for measuring serum antibodies to pneumococcal polysaccharides. Clin Vaccine Immunol 17:862-869. Http://dx.doi.org/10.1128/CVI.00022-10.
17. Zhang X, Simmerman K, Yen-Lieberman B, Daly TM. 2013. Impact of analytical variability on clinical interpretation of multiplex pneumococcal serology assays. Clin Vaccine Immunol 20:957-961. Http://dx.doi.org/10.1128/CVI.00223-13.
18. Daly TM, Pickering JW, Zhang X, Prince HE, Hill HR. 2014. Multilaboratory assessment of threshold versus fold-change algorithms for minimizing analytical variability in multiplexed pneumococcal IgG mea-surements. Clin Vaccine Immunol 21:982-988. Http://dx.doi.org/10.1128 /CVI.00235-14.
19. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. 2000. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 30:100-121. Http: //dx.doi.org/10.1086/313608.
20. Pickering JW, Larson MT, Martins TB, Copple SS, Hill HR. 2010. Elimination of false-positive results in a luminex assay for pneumococcal antibodies. Clin Vaccine Immunol 17:185-189. Http://dx.doi.org/10.1128 /CVI.00329-09.
21. Choo S, Seymour L, Morris R, Quataert S, Lockhart S, Cartwright K, Finn A. 2000. Immunogenicity and reactogenicity of a pneumococcal conjugate vaccine administered combined with a haemophilus influenzae type B conjugate vaccine in United Kingdom infants. Pediatr Infect Dis J 19:854-862. Http://dx.doi.org/10.1097/00006454-200009000-00009.
22. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, Takala A, Kayhty H, Karma P, Kohberger R, Siber G, Makela PH. 2001. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 344:403-409. Http://dx.doi.org/10.1056/NEJM200102083440602.
23. Rennels MB, Edwards KM, Keyserling HL, Reisinger KS, Hogerman DA, Madore DV, Chang I, Paradiso PR, Malinoski FJ, Kimura A. 1998. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 101:604-611. Http: //dx.doi.org/10.1542/peds.101.4.604.
24. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W, Austrian R, Edwards K. 2000. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19:187-195.
25. Moore CE, Paul J, Foster D, Mahar SA, Griffiths D, Knox K, Peto TE, Walker AS, Crook DW. 2014. Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England. J Infect Dis 210:1001-1011. Http://dx.doi.org/10.1093/infdis/jiu213.
26. Tan TQ. 2014. Invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England. J Infect Dis 210:999-1000. Http://dx.doi.org/10.1093/infdis/jiu218.
27. Beck SC. 2013. Making sense of serotype-specific pneumococcal antibody measurements. Ann Clin Biochem 50:517-519. Http://dx.doi.org/10.1177 /0004563213500241.
28. Orange JS, Ballow M, Stiehm ER, Ballas ZK, Chinen J, De La Morena M, Kumararatne D, Harville TO, Hesterberg P, Koleilat M, McGhee S, Perez EE, Raasch J, Scherzer R, Schroeder H, Seroogy C, Huissoon A, Sorensen RU, Katial R. 2012. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 130:S1-S24. Http://dx.doi.org/10.1016/j.jaci.2012.07.002.
29. Zielen S, Buhring I, Strnad N, Reichenbach J, Hofmann D. 2000. Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine. Infect Immun 68:1435-1440. Http://dx.doi.org/10.1128/IAI.68.3.1435-1440.2000.
30. Hill HR, Pickering JW. 2013. Reference laboratory agreement on multianalyte pneumococcal antibody results: an absolute must! Clin Vaccine Immunol 20:955-956. .